Amarin | AMRN - Equity Capital And Reserves


Amarin reported $458.89M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 458.89M 6.03M Sep/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025